Vision-Related Function after Ranibizumab Treatment by Better- or Worse-Seeing Eye: Clinical Trial Results from MARINA and ANCHOR

摘要: Objective To examine the effects of ranibizumab on National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) scores in neovascular age-related macular degeneration (AMD) according to whether study eye was better- or worse-seeing at baseline. Design Within 2 randomized, double-masked clinical trials (MARINA and ANCHOR), NEI VFQ-25 administered 0, 1, 2, 3, 6, 9, 12, 18, 24 months. Participants We included 646 MARINA 379 ANCHOR patients. Intervention Patients were randomized 1:1:1 monthly intravitreal (0.3 0.5 mg) control (sham injections for MARINA; photodynamic therapy [PDT] with verteporfin ANCHOR). Main Outcome Measures Mean change from baseline 12 Results Across all treatment arms, 21% 38% enrolled eyes better-seeing eye. At 24-month follow-up visit, mean composite seemed be better than both (8.4 [95% confidence interval (CI), 5.2–11.6], 7.5 CI, 3.7–11.4], −9.4 −12.5 −6.3] 0.3-mg, 0.5-mg, sham groups, respectively) (1.7 −1.1 4.4], 1.7 −0.7 4.1], −5.4 −7.9 −2.8] MARINA, as well (11.3 5.3–17.3], 13.3 7.7–19.0], −2.7 −9.0 3.7] PDT respectively). When treated ANCHOR, such differences could not detected months (1.3 −1.7 4.2], 2.6 6.3], 0.1 −3.5 Conclusions Analysis patient perception vision-related function phase III evaluating AMD demonstrates improved patient-reported outcomes regardless is onset treatment, supports lesions ranibizumab, even those Financial Disclosure(s) Proprietary commercial disclosure may found after references.